King Charles III is receiving ongoing cancer treatment, progressing positively. Despite health challenges for the royal family, he’s maintained royal duties, recently making a lighthearted remark about his well-being. The royal family’s openness about their health battles promotes cancer awareness.
Russia is set to introduce a free, personalized mRNA cancer vaccine in early 2025. Tailored to individual patients’ tumors, the vaccine aims to stimulate an immune response against cancer cells. This development comes amid a global surge in cancer cases and underscores the increasing focus on personalized cancer therapies. The vaccine’s exact applications and name remain undisclosed, but it represents a significant step in the fight against cancer.
The global microwave ablation (MWA) devices market is experiencing phenomenal growth, projected to reach US$1 billion by 2034, driven by the increasing demand for minimally invasive cancer treatments and technological advancements. This report details market trends, key players, and regional insights.
Cricketer-turned-politician Navjot Singh Sidhu and his wife face a ₹850 crore legal notice for claims that a special diet cured his wife’s stage 4 cancer in just 40 days. The Chhattisgarh Civil Society demands proof within seven days.
Agenus Inc. (AGEN) stock surged over 16% after securing a $22 million mortgage and unveiling a strategic realignment plan focused on its promising BOT/BAL cancer therapy. The plan aims to significantly reduce cash burn and accelerate development of this key asset.
Lung cancer remains a leading cause of cancer-related deaths worldwide. This article explores the alarming rise in cases, focusing on the roles of air pollution and tobacco, examines the latest diagnostic and treatment advancements, and offers crucial preventative measures.
Goldman Sachs has upgraded BioNTech (BNTX) to Buy, citing the company’s BNT327, an immuno-oncology asset in clinical development. Data from Summit Therapeutics and Akeso for ivonescimab (PD-1xVEGF bispecific) has shown potential to challenge standard-of-care regimens across various solid tumors, sparking interest in BioNTech’s bispecific drug. Goldman analysts believe BNT327 has the potential to drive BioNTech toward becoming a leading player in oncology, making current stock levels an attractive entry point for investors.
A 49-year-old virologist, Beata Halassy, successfully treated her breast cancer using a self-administered treatment involving lab-grown viruses. Her case, published in the journal ‘Vaccines’, sparked a heated discussion about the ethics of self-experimentation and the potential for unconventional cancer therapies.
Dragonfly Therapeutics, a clinical-stage biotech company, showcased preclinical data for its novel immunotherapies, DF6215 and DF9001, at the Society for Immunotherapy of Cancer (SITC) Annual Conference. DF6215, an engineered IL-2 cytokine, demonstrated superior therapeutic benefits compared to traditional IL-2 therapies, while DF9001, an EGFR-targeting TriNKET, exhibited potent anti-tumor activity through both EGFR-signal inhibition and immune-mediated mechanisms. Both candidates showed promising safety profiles, highlighting their potential for treating advanced solid tumors.
Macrogenics, a biotechnology company focused on cancer treatments, is set to release its quarterly earnings on November 5th. Analysts anticipate an EPS of $0.21, but investors will be closely watching for guidance, past performance trends, and the company’s market position compared to peers.
